Letter to House Energy and Commerce Committee Opposing Amendments to H.R. 2430, the FDA Reauthorization Act
In many ways, U.S. health care is the envy of the world—it has helped many individuals live longer than ever and enjoy a better quality of life than previously possible. However, we continue to face the challenge of making quality health care more affordable, more accessible, and more reliable for all Americans. The Chamber is focused on promoting effective private sector solutions to our health care challenges that will help control costs, expand access, and improve the quality of care.
Wellness and chronic disease management programs in the workplace play a critical role in improving the nation's health and productivity
On May 23, 2017, the U.S. Chamber of Commerce sent this letter to Senate Finance Committee Chairman Orrin Hatch that outlined several legislative reform recommendations as the Senate moves forward with crafting their own proposal for the repeal and replacement of Obamacare.
Consumers who buy their own insurance may soon be forced out of the market.
On Friday, May 19, the Chamber, along with 7 other trade associations representing insurers, hospitals, physicians and employers, sent a letter to U.S. Department of Health and Human Services Secretary Tom Price.
On Friday, May 19, the Chamber, along with 7 additional trade associations representing insurers, hospitals, physicians and employers, sent a letter to Office of Management and Budget Director Mick Mulvaney.
This letter was sent to the members of the House Subcommittee on Health opposing any amendments that may be offered to the Food and Drug Administration Reauthorization Act of 2017 that would allow the importation of foreign pharmaceuticals into the United States or that would undermine the preemptive authority of federal food and drug regulations. The Subcommittee is marking up the bill tomorro
This letter was sent to the members of the Senate Committee on Health, Education, Labor, and Pensions opposing amendments that may be offered to S. 934, the Food and Drug Administration Reauthorization Act, that would allow the importation of foreign pharmaceuticals into the United States or that would undermine the preemptive authority of federal food and drug regulations.
During the first 100 days of this year, we embarked on a small business listening tour around the country.
WASHINGTON, D.C. —U.S. Chamber of Commerce President and CEO Thomas J. Donohue issued the following statement today following House passage of the “American Health Care Act”: